Method for prolonging anterior chamber anaesthesia and pupil dilatation experimentally
SUBSTANCE: anterior chamber anaesthesia and pupil dilatation accompanying anterior eye segment surgeries experimentally involve a preoperative administration of a composition in an amount of 0.1-0.2 ml representing 0.005% 1-(3-pyrrolidinopropyl)-2-phenylimidazo[1,2-a]benzimidazole dihydrochloride into the anterior eye segment. The composition is prepared in 1% viscoelastic solution, visiton PEG.
EFFECT: prolonging anaesthetic effect and pupil dilatation with no mydriatics used.
The present invention relates to experimental medicine, namely to pharmacology and ophthalmology, and can be further used for prolonging prednamerennoe anesthesia and pupil dilation operations on the anterior segment of the eye.
While used in cataract surgery block anesthesia (Sultanova, retro and parabulbar) in combination with athralgia potential risk of numerous complications: the formation of retro and parabulbar hematoma, orbital infection, perforation of the sclera capsules eyeball sharp injection needle, the needle trauma to the optic nerve, increased intraocular pressure due to the additional volume injected anesthetic, occlusion of the Central retinal artery, persistent postoperative mydriasis, ptosis, postoperative diplopia and so on [Anisimov, S. Y., Anisimov, S. I., Colander Y. P. Effectiveness of epibulbar anesthesia in outpatient cataract surgery and glaucoma // Modern technologies in cataract surgery: Sat. scient. Tr. - M., 2002. - S. 21-28; Bakunin N. A., Ivanov, I. L. Rational method of local anesthesia in ophthalmology // VIII the age of three. scientific and practical use. proc. from INTL. participation "Fedorovskii readings - 2009": Sa. scient. articles / FGI "IRTC "eye microsurgery". - M., 2009. - S. 322-323].
Execution block anesthesia causes of the patient, except for b is Li, fear, psychological discomfort, unexpected vegetative reactions [Bakunin N. A., Ivanov, I. L. Rational method of local anesthesia in ophthalmology // VIII the age of three. scientific and practical use. proc. from INTL. participation "Fedorovskii readings - 2009": Sa. scient. articles / FGI "IRTC "eye microsurgery". - M., 2009. - S. 322-323; Kaganova L. O., Jaber N.A., Chuguev M. C., kuniji B. M., Romanenko B. C. advantages of injection-free anesthesia in the outpatient ophthalmic surgery // Modern technologies in cataract surgery: Sat. scient. Tr. - M., 2002. - S. 155-161]. In recent years, in ophthalmic surgery are increasingly being used in chamber anesthesia [Canavan K. S., A. Dark, Garrioch MA. Sub-Tenon's administration of local anaesthetic: a review of the technigue // Br. J. Anaesth. - 2003. - Vol.17. - P. 1003-1107; Lo Martire N., Savastano, S., L. Rossini et al. Topical anaesthesia for cataract surgery with photoemulsification: lidocain 2% versus ropivacaine 1%: preliminary results // Minerva Anaesthesiol. - 2002. - Vol.68. - P. 529-535.]. The only local anesthetic that is allowed to be used in the internal chamber of the anesthetic is lidocaine. Based on this research in the mentioned direction have important theoretical and practical value.
Well-known local anesthetic for prednamerennoe anesthesia for surgical intervention associated with cataract extraction and intraocular lens implantation (Koch P. S. Anterior chamber irrigation with unpreserved 1% lidocaine for anesthesia during cataract surgery. J. Cataract Refractive Syrg 1997; 23, 551-554). what about the time of the operation in the anterior chamber of the eye injected with 1% aqueous solution of lidocaine in the amount of 0.25-0.5 ml
Known composition of local anaesthetics isocaine with visitanos-PEG used for surface anesthesia [Galenko-Yaroshevsky P. A., Lisitsyn N. P., Takhchidi H. P. Activity of combinations of isocaine with visitanos-PEG under conditions of anesthesia surface method // Kuban scientific medical Bulletin, KSMU, 2009, №2. - S. 66-69].
The closest analogue adopted patent No. 2147876 (Fedorov, S. N.; Malyugin B. E.; Bagrov, S. N.; Maklakov, I. A.; Wersin A. A., 2000), according to which the pharmaceutical composition for the treatment of pain in various types of ophthalmic surgeries and procedures, including local anestis, further comprises viscoelastic and heparin in the following ratio, wt.%: a local anesthetic is 0.01 to 4.0; heparin - 5-500 units/ml; viscoelastic rest. May be injected into the anterior chamber of the eye, and is applied to its surface.
The disadvantage of the application of local anesthetics as proposed is that with the passage of a significant amount of irrigation solution through the camera eye, during such operation stages, as hydrodissection, aspiration and irrigation during the leaching lenticular masses, anesthetics rapidly washed away from the anterior chamber of the eye, the patient begins to feel pain, a narrowing of the pupil, which requires re-introduction of anesthetic. In addition, the probability is proniknoveniya aqueous solution of anesthetic to the posterior segment of the eye and the toxic effect on the optic nerve and retina. According closest analogue (patent No. 2147876) in the composition is included heparin, which may cause the occurrence of bleeding in case of accidental trauma to the iris.
The task of the invention is to achieve a deep and prolonged anaesthesia and dilatation of the pupil without the use of Mydriatics throughout surgery on the anterior segment of the eye, as well as the elimination of pain up to 2 hours in the postoperative period. The method is tested on rabbits.
The essence of the invention is that immediately before the beginning of the operation in front of the camera and impose 0.1-0.2 ml pre-seasoned during the day song 0.005% solution of dihydrochloride of 1-(3-pyrrolidinyl)-2-phenylimidazo[1,2-a]benzimidazole, prepared on viscoelastic - visitone-PEG.
The technical result of the application of the proposed method is the increase of time (up to two hours) anesthetic effect and pupil dilation achieved with a single introduction of the proposed composition in the anterior chamber of the eye, allowing for use in medicine to increase the comfort level of both patient of the surgeon during surgery, and to provide analgesia in the postoperative period up to 2 hours.
The advantage of the inventive method is that achieved Bo is significant for the depth and duration of analgesic effect during surgery on the anterior segment of the eye, and in the postoperative period, as well as pupil dilation without using Mydriatics; reducing toxic effects of anesthetic to the eye tissue. Used as a solvent anesthetic agent viscoelastic - vision-PEG protects the corneal endothelium during surgical manipulation.
The proposed pharmaceutical composition for the treatment of pain and pupil dilation when cell anesthesia of the eye can be further used when conducting eye surgery (cataract extraction with intraocular lens implantation, removal of intraocular foreign body, vitrectomy, penetrating keratoplasty, and others). After surgical intervention, the pharmaceutical composition should clean up the irrigation solution.
The method is tested in experiments at 160 eyes 80 rabbits, including 40 of the eye, the cornea which were subjected to transmission electron microscopy, which was objective evidence of safety and advantages of this method over existing.
Example 1. Experiment. Rabbit weighing 3 kg in the right eye through the paracentesis put 0.1 ml of the proposed composition, which led to full anaesthesia and dilatation of the pupil. Anesthesia was checked by algesimeter every 5 minutes Full anesthesia lasted more than 2 hours. The pupil remained wide for 1.5 the Asa. After anesthesia of the cornea was autocaravana and investigated using transmission electron microscopy. The study found that the ultrastructure of all layers of the cornea without significant morphological changes.
Example 2. Experiment. Rabbit weighing 4 kg in the left eye through the paracentesis introduced 0.2 ml of the proposed composition, which led to full anaesthesia and dilatation of the pupil. Anesthesia was checked by algesimeter every 5 minutes Full anesthesia lasted more than 2 hours. The pupil remained wide for 1.5 hours. After anesthesia of the cornea was autocaravana and investigated using transmission electron microscopy. The study found that the ultrastructure of all layers of the cornea without significant morphological changes.
The way prolonged prednamerennoe anesthesia and expansion of the pupil of the eye in the experiment, characterized in that the front chamber and injected with 0.1-0.2 ml of the composition, representing 0.005% solution of dihydrochloride of 1-(3-pyrrolidinyl)-2-phenylimidazo[1,2-a]benzimidazole, prepared with 1% solution viscoelastic - visiona-PEG.
FIELD: veterinary medicine.
SUBSTANCE: intramesovarian blockade of ovarian and cranial uterine nerves is carried out by laparotomy and administration in the mesovarium of 0.5-1% solution of novocaine or lidocaine. Blockade is carried out by inserting the needle of the syringe into the mesovarium in the vicinity of the ovarian bursa and uterine horn at an acute angle to the surface of the ovarian mesenterium to a depth of 3-4 cm. At that 3 ml of anaesthetic is administered to small breeds of dogs and fur-bearing animals, and from 3 to 9 ml of anaesthetic is administered to large and giant breeds of dogs as from one and from the opposite side of the body.
EFFECT: effective implementation of intramesovarian blockade by taking into account the anatomical and the breed features of the animal category.
SUBSTANCE: patient is laid on his/her side opposite a block region. A guide mark is a vertical line in a projection of Petit's triangle from the twelfth rib to a wing of ilium. A needle is pricked into the skin on the vertical line at 1.5-2.5cm above the wing of ilium. 0.25% Novocaine is administered in layers into the skin and subcutaneous fat. The needle is advanced into the lumbar region from back to front in the medial direction along the lateral edge of broadest muscle of back at 6-8cm. Novocaine 120ml is administered into the lower order of the lumboiliac fossa formed in this region.
EFFECT: effective and safe pain management in the given category of patients by providing the required Novocaine concentration in the retroperitoneal space.
1 dwg, 1 ex
SUBSTANCE: aqueous composition for anaesthesia is proposed, which comprises propofol as an active agent, the PEG-660-12-hydroxystearate as a solubiliser, benzyl alcohol, or chloroethanol or parabens as preservative, the tocopherol and arginine or glycine at a specific content of components wt %. The GABA agonists can be additionally added to the composition, e.g. aminophenyl-butyric acid, local anesthetics such as lidocaine, alpha-2-adrenoceptor agonists such as xylazine. The method is proposed for implementing anaesthesia comprising administering to a patient of an effective amount of the claimed composition.
EFFECT: invention provides low toxicity of dosage form and high efficiency.
5 cl, 3 tbl, 1 ex
SUBSTANCE: radionuclide indicator is administered to record the dynamics of its distribution in limb tissues by a radionuclide method. The examination is performed at rest and during a load test. The load test represents an epidural block by gradual administration of bupivacaine 25-30 mg between L2-L3 vertebrae for 5-7 minutes. That is followed by measuring a blood flow as a percentage of its value to the same level in an analogous segment of a collateral limb.
EFFECT: qualitative assessment of the circulation reserve in various categories of patients, including disabled ones by inhibiting sympathetic and minimally sensory activity with maintaining the patients' motor activity.
2 dwg, 2 ex
SUBSTANCE: invention refers to medicine, namely to abdominal surgery and anaesthesiology, and can be used where it is necessary to anaesthetise after the prosthetic hernioplasty for median postoperative ventral hernias. That is ensured by placing an endoprosthesis under the aponeurosis, a polyvinylchloride catheter is placed into the formed spaced around the periphery of a postoperative wound in the form of an oval above the endoprosthesis plane at 2.5-3 cm from its edges. Along its full length, the catheter has multiple side holes. Single openings are created in a projection of a lower corner of the wound, and the catheter ends are brought out onto the skin. An inlet of the catheter is attached to a local anaesthetic dosage device by means of a cannula. That is followed by a controlled prolonged irrigation with 2.5% Ropivacaine 20 ml every 6-8 hours during 2-3 days.
EFFECT: method enables the adequate postoperative anaesthesia, as well as the length of the postoperative intestinal distention by providing the uniform controlled administration of the local anaesthesia solution.
7 dwg, 1 ex
SUBSTANCE: invention relates to medicine, namely to anaesthesiology and surgery, and can be used in case of anaesthesia necessity in patients after herniorrhaphy with inguinal access in case of inguinal hernias. For this purpose after the main stage of operation - hernioplasty, before suturing of the aponeurosis of the external oblique abdominal muscle, through subcutaneous adipose cellular tissue a puncture of 1 cm more medially and 1 cm higher than the anterior-superior iliac spine is made. A multiperforated catheter is introduced through the puncture under finger and visual control in such a way that its distal end is near the pubic tubercle. The catheter is placed under the aponeurosis of the external oblique abdominal muscle in the inguinal canal above and parallel to the spermatic cord in men or the round ligament of uterus in women. All the side holes of the catheter must be located in the subaponeurotic space. The first 48 hours of the post-operation period the local anaesthetic is continuously introduced by drop infusion at a rate of 2-4 ml/h or by bolus introduction in a dose of 10 ml each 4-6 hours through the catheter. After 48 hours the catheter is removed.
EFFECT: method provides adequate anaesthesia in the said category of patients in the post-operation period without application of additional anaesthetic preparations due to blockade of ilioinguinal, ilioceliac and hollow branch of genitofemoral nerves.
2 dwg, 2 ex
SUBSTANCE: group of inventions refers to medicine, and may be used in treating the patients suffering headaches and facial pains. There are presented versions of a drug delivery device comprising an injector a first end of which is left outside patient's nasal passages. Another end of the injector comprises one or more holes for spraying a drug upwards, and/or to the side, and/or to the front towards a sphenopalatine ganglion, an input device interacting with a patient's nostril and comprising a canal for receiving the injector. Additionally, the device can comprise a handle connected to the input device and provided for receiving the canal of the input device. The injector can move between a storage position before the interaction, and an interaction position related to the interaction. There are also presented versions of the method of using the above device that involve introducing the injector through the nasal passage into median and/or posterior and/or inferior region in relation to the patient's sphenopalatine ganglion, and spraying the drug.
EFFECT: group of inventions provides faster and more effective headache and facial pain relief by safe and accurate drug delivery of the therapeutic substances blocking the sphenopalatine ganglion.
49 cl, 4 dwg, 30 ex
SUBSTANCE: invention relates to a novel biologically active 2,6-dimethylanilide of N-cyclohexylpyrrolidine-2-carboxylic acid, having surface, infiltration and conduction anaesthesia activity, considerably better than bupivacaine and ropivacaine with the same or less toxicity.
EFFECT: improved compounds.
FIELD: medicine, pharmaceutics.
SUBSTANCE: what is presented is a pharmaceutical composition in the form of a spray for treating a damage by non-lethal irritants (e.g. pelargonic acid morpholide), containing pediphene in the following proportions, wt/volume %: pediphene hydrochloride 0.01-10.0; sodium chloride 0.1-10.0; water for injections up to 100 ml. What is shown is the efficacy of pediphene in compliance with the declared application ensured by the local anaesthetic effect of the drugs.
EFFECT: drug preparation has no allergenic and immunotoxic properties.
3 dwg, 40 tbl
SUBSTANCE: invention refers to medicine, namely anesthesiology, intensive therapy and endosurgery, and may be used in patients in need of endoscopic transpapillary intervention. That is ensured by an intravenous infusion therapy with crystalloid solutions in the amount of 800-1200 ml. An epidural space is punctured and catheterised at the level of Th VIII - Th IX with the catheter moved by 4-5 cm in the cranial direction. A local anaesthetic solution and Clopheline 100 mcg are introduced through the epidural catheter at the level of Th V - Th X 20 minutes before the endoscopic transpapillary intervention. It is followed by pre-medication enabled by introducing 0.1% atropine 0.5-1 ml and 0.5% relanium 1-2 ml, and the patient is wheeled into a catheterisation laboratory. After the endoscopic transpapillary intervention completed, the patient is transferred into an intensive therapy unit wherein prolonged epidural analgesia is enabled by introducing 0.5-1% lidocaine 10 ml into the epidural space every 4 hours. If observing no clinical manifestations of postoperative pancreatitis, the epidural catheter is removed, and the patient is transferred into a department of surgery for symptomatic treatment.
EFFECT: method enables preventing acute postoperative pancreatitis following such interventions due to action of a general mechanism of pathogenesis of the given pathology.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to compounds of formula , where R1 represents hydroxyadamantyl, methoxycarbonyladamantyl, carboxyadamantyl, aminocarbonyladamantyl or aminocarbonylbicyclo[2.2.2]octanyl and where A represents CR5R6; or phenyl, chlorobenzyl, benzyl, chlorophenylethyl, phenylethyl, difluorobenzyl, dichlorophenyl, trifluoromethylphenyl or difluorophenylethyl and where A represents CR5R6; R2 and R3 together with nitrogen atom N* and carbon atom C*, which they are bount to, form group or ; R4 represents hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, arylalkyl, arylalkoxygroup, arylalkoxyalkyl, hydroxyalkyl, aryl, heteroarylalkyl, heteroaryloxyalkyl, substituted aryl, substituted heteroarylalkyl or substituted heteroaryloxyalkyl, where substituted aryl, substituted heteroarylalkyl and substituted heteroaryloxyalkyl are substituted with 1-3 substituents, independently selected from alkyl, cycloalkyl, cyanogroup, halogen, halogenalkyl, hydroxygroup and alkoxygroup; R5 represents hydrogen; R6represents hydrogen; as well as to their pharmaceutically acceptable salts and esters, which can be used as 11b-HSD1 inhibitors.
EFFECT: obtaining compounds which can be used as 11b-HSD1 inhibitors.
9 cl, 1 tbl, 103 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to organic chemistry, namely to a heterocyclic compound of formula I and its pharmaceutically acceptable salt, wherein if a chemical valency permits, i represents 1 or 2, R1 represents H; a linear (C1-C4) alkyl group, R2 represents H, Cl or F, X represents either N, or CR3, R3 represents H; halogen; a linear (C1-C4) alkyl or (C1-C4) alkoxyl group, Y represents Z represents O or NRx, Rx represents H or a linear or branched (C1-C4) alkyl, k is equal to 2, 3 or 4, n and p independently represents 2, and a sum of n+p cannot exceed 4, T represents H or a linear (C1-C4) alkyl group; T′ represents a linear C1-C3 alkyl chain substituted by either (C1-C6)-dialkylaminogroup, or a 5-6-merous saturated heterocycle containing one nitrogen atom and optionally containing the second heteroatom specified in O, such a heterocyclic ring is optionally substituted by a (C1-C4) alkyl chain at nitrogen atoms; or a 5-merous saturated heterocycle containing one nitrogen atom, such a heterocyclic ring is optionally substituted by a (C1-C4) alkyl chain at nitrogen atoms; r represents zero, 1; R′ represents di(C1-C4)alkylamino, (C1-C4)alkoxy; except for the compounds specified in the clause. The invention also refers to a pharmaceutical composition based on the compound of formula (I), using the compound of formula (I) and to a method of treating diseases, in which the hedgehog signalling pathway modulation is effective.
EFFECT: there are prepared new heterocyclic compounds possessing t effective biological properties.
20 cl, 193 ex
SUBSTANCE: invention relates to pharmaceutics and medicine and use of tricyclic imidazo[1,2-a]benzimidazole derivatives of general formula I or 1,3-disubstituted 2-aminobenzimidazolium halides of general formula II as an agent having cardioprotective action with high efficiency.
EFFECT: high efficiency.
3 cl, 1 tbl, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the chemical-pharmaceutical industry and represents a method of obtaining a complex preparation for the application in veterinary, possessing immunomodulating and antiseptic properties, which includes mixing succinic acid, levamisole and formalin in distilled water with the following component ratio, wt %: levamisole - 3.0%-3.5%; succinic acid - 2.0%-2.5%; formalin - 0.3%-0.5%, distilled water - the remaining part; sterilisation of the solution by autoclaving is performed in a mode of 1 atm for 20 minutes.
EFFECT: elaboration of the method of obtaining the complex preparation for the application in veterinary, possessing immunomodulating and antiseptic properties.
SUBSTANCE: disclosed is use of 2-(4,5-dichloroimidazolyl-1)-5-nitropyridine as an anti-protist agent. Anti-protist activity of 2-(4,5-dichloroimidazolyl-1)-5-nitropyridine is equal to 15.6 mcg/ml for Colpoda steinii. The substance can also relate to moderately toxic medicinal drugs.
EFFECT: high anti-protist activity.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and medicine, and concerns using 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydroimidazo[4,5-c]quinolin-1-yl)phenyl]propionitrile or 8-(6-methoxypyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifluoromethylphenyl)-1,3-dihydroimidazol[4,5-c]quinolin-2-one.
EFFECT: preparing a pharmaceutical formulation for treating a VBGF-stimulated angiogenic disease, a method of treating a VBGF-stimulated angiogenic disease and using the above compounds for the high-efficacy treatment of the above diseases.
5 cl, 4 dwg, 4 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: there are described new polycyclic compounds, pharmaceutically acceptable salts thereof of general formula wherein R1 -phenyl, pyridyl, optionally substituted, or C3-7-cycloalkyl; R2 -H, -CH2R3, -C(=O)R3, -C(=O)N(R4)R3, and -SO2-pyridyl, wherein R3-H, C1-6 alkyl, C2-6 alkenyl, C3-7-cycloalkyl, -(CH2)m-phenyl -(CH2)m-(5-, 6- or 9-member heterocyclyl with 1-3 heteroatoms N, O or S); m is equal to 0-6; R4 -H; X represents O or S; the alkyl, alkenyl, cycloalkyl, phenyl and heterocyclyl groups may be substituted by one or more substitutes. A together with atoms whereto attached forms phenyl or heteroaryl with 1 or 2 nitrogen atoms, optionally substituted; B-C means -CH2-(CH2)z-, wherein z is equal to 1 or 2; D represents -CRIIIRIV-, wherein RIII and RIV are identical, and mean CH3 or H; or RIII and RIV together with the atom C whereto attached form a 3-member cycloalkyl ring, a pharmaceutical composition containing them, and the use of the above compounds for treating viral RSV infections.
EFFECT: new polycyclic compounds are described.
24 cl, 4 tbl
FIELD: medicine, pharmaceutics.
SUBSTANCE: there are presented: agent applicable for treating or preventing diseases involving the enzyme dipeptidyl peptidase-IV (DPP-IV) representing Limiglidol (the same 9-diethylaminoethyl-2,3-dihydroimidazo[1,2-a]benzimidazole dihydrochloride, the same diabenol), a pharmaceutical composition thereof for the same application, using Limiglidol for preparing the pharmaceutical composition for the same application and using Limiglidol for normalising blood incretins (e.g., GLP-1, GIP decomposed under action of DPP-IV). What is shown is a high selectivity of Limiglidol in relation of DPP-IV.
EFFECT: invention enables using Limiglidol for preventing, delaying progression and/or treating conditions the pathogenesis of which involves the enzyme DPP-IV, including sterility, polycystic ovary syndrome, growth disorder, asthenia, arthritis, allograft rejection, autoimmune diseases (sclerodermia and multiple sclerosis), a variety of immunomodulatory diseases (lupus erythematosus and psoriasis), AIDS, intestinal diseases (necrotic enteritis, microvilli involving diseases or abdominal diseases), intestinal inflammatory syndrome, atrophy, etc.
10 cl, 1 dwg, 2 tbl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry and represents a vitamin additive containing vitamin B1, vitamin B2, nicotinic acid, vitamin B6, biotin and pantothenic acid; and wherein the weight ratio of biotin to vitamin B1 makes 1:20 to 1:25; wherein the weight ratio of biotin to vitamin B2 makes 1:25 to 1:30; wherein the weight ratio of biotin to nicotinic acid makes 1:310 to 1:330; wherein the weight ratio of biotin to vitamin B6 makes 1:30 to 1:35; wherein the weight ratio of biotin to pantothenic acid makes 1:110 to 1:130.
EFFECT: invention provides increasing activity, reducing the environmental stress effects, improving immunity of an individual, reducing the cases, the length and severity of respiratory infections.
13 cl, 1 ex
SUBSTANCE: invention refers to medicine and may be used to improve the adaptation possibilities and to correct the psychofunctional state in the patients with harmful working conditions. That is ensured by recommending a relaxed or partial load or motion state. Health food from Diet No.5, intake of low-mineralised (3.7 g/dm3) low-carbonate sulphate-hydrocarbonate sodium-calcium mineral water of 'Slavyanovskaya' source (Zheleznovodsk mineral water), 3.3 g/kg of body weight (200-250 ml) per one intake, 45 minutes before meals, 3 times a day. The patient takes baths with mineral water of the same composition at water temperature 36-37°C for 15 minutes, every second day, in the therapeutic course consisting of 10 procedures. The aromatherapy-assisted psychological autotraining sessions are prescribed for 14 days. Furthermore, Adaptol is prescribed for 14-day intake in a dose of 500 mg 3 times a day.
EFFECT: invention provides an improved adaptation, autonomic regulation, peroxide homeostasis, digestive functions, mental and emotional status of the patients exposed to the adverse effects of environmental factors due to the integrated treatment.
5 tbl, 3 ex
SUBSTANCE: invention refers to medicine, particularly ophthalmology, and can be used to treat a low-activity fibrovascular membrane of the macular area. The method involves performing subtotal vitrectomy, removing the fibrovascular membrane, packing the retina with a perfluoroorganic compound followed by replacing by air and SF6 gas in an amount of 2 ml and performing and a laser endolasercoagulation of the retina. That is preceded by performing iridectomy and separating the pigment layer of the diameter of 1 mm. That involves preparing a suspension of 0.85% NaCl 0.2 ml and the pigment layer. The prepared suspension is introduced to replace the removed fibrovascular membrane before packing the retina with the perfluoroorganic compound and performing endolasercoagulation.
EFFECT: using the invention provides the partial restoration of the morphological structure and functional adequacy of the retina involved into the developing fibrovascular tissue.